WASHINGTON–(BUSINESS WIRE)–Today at the National Minority Quality Forum (NMQF) Summit on Health Disparities and Health Braintrust, Gary A. Puckrein, Ph.D., President and CEO of NMQF, announced a new paper entitled “Late-Stage Diagnosis of Unscreened …
Author: Business Wire
Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon shareholders approve all binding resolutions at the 2021 Annual General Meeting
UnitedHealthcare Enhances Integration of Medical and Specialty Benefits, Helping Improve Health Outcomes and Affordability
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare has introduced various enhancements to its integrated approach to medical and specialty benefits, providing members with a more simplified experience and enabling employers to help improve employee h…
Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
GENEVA–(BUSINESS WIRE)–Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
LENSAR to Hold First Quarter 2021 Financial Results Conference Call on Wednesday, May 5, 2021
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fir…
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fi…
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Global Dry Eye Disease Market (2021 to 2026) – Insights, COVID-19 Impact, Competition and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Disease (DED) Market – Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid -19 Impact, Competition and …
BJ’s Wholesale Club Launches New Online Shopping Experience for BJ’s Optical
WESTBOROUGH, Mass.–(BUSINESS WIRE)–BJ’s Wholesale Club (NYSE: BJ), a leading operator of membership warehouse clubs in the Eastern United States, today announced a new online shopping experience for BJ’s Optical, which allows shoppers to purchase sun…
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Kubota Vision to Present at the Ophthalmology Innovation Summit (OIS) Myopia Innovation Showcase
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that Ryo Kubota, MD, PhD, Chairman, Pre…
Eye Health America Continues Expanding Across the Southeast Partnering With the Eye Care Center in Upstate South Carolina
GREENVILLE, S.C.–(BUSINESS WIRE)–Today, Eye Health America (EHA), a leading eye care practice management organization in the Southeast, welcomes Drs. William Milford and Marion K. Williams of The Eye Care Center, into its business family. The Eye Car…
Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)– #ARVO2021–Allegro Ophthalmics will present four scientific posters on risuteganib, its lead investigational compound in retina, during the 2021 ARVO Meeting.
Biomarck’s MARCKS Inhibitors for Uveitis to be Presented at the 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
NEWTOWN, Pa.–(BUSINESS WIRE)– #cytokinestorm–Biomarck’s MARCKS inhibitors for uveitis will be presented at the 2021 Annual Meeting of Association for Research in Vision and Ophthalmology (ARVO).
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Glaukos Announces the Release of its 2020 Sustainability Report
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
CHMP empfiehlt EU-Zulassung von Enspryng (Satralizumab) von Chugai für Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) hat heute bekannt gegeben, dass Roche eine Mitteilung vom Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) erhalten hat, wonach dieser die Zulassung…
CHMP recommande l'approbation par l'UE de l'Enspryng (satralizumab) de Chugai pour le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé aujourd’hui que, selon une notification adressée à la société Roche, le comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments (EMA) a recomma…